We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI-Based Pathology Diagnosis Tool Detects Seven Types of Gastric Cancer

By LabMedica International staff writers
Posted on 09 Sep 2022
Print article
Image: A diagnostic tool under development has succeeded in expanding its AI detection to seven types of gastric cancer (Photo courtesy of Evident)
Image: A diagnostic tool under development has succeeded in expanding its AI detection to seven types of gastric cancer (Photo courtesy of Evident)

There is increasing demand for diagnostic tools that can help reduce the workload of pathologists. Now, researchers developing an AI-based pathology diagnostic tool have succeeded in expanding its AI detection to seven types of gastric cancer, highlighting its versatility for a range of pathology applications.

Evident (Waltham, MA, USA), a wholly owned subsidiary of Olympus Corporation, announced the latest results from its ongoing joint research program to create an AI-based pathology diagnostic tool at the 20th annual meeting of the Japanese Society of Digital Pathology. In 2017, Evident along with collaborators had begun to develop the AI-based pathology diagnosis tool. The first testing phase showed the diagnostic tool could successfully identify adenocarcinoma tissue from pathology whole-slide images. As part of the second research phase that began in November 2020, the tool was tested on 2,717 pathology whole-slide images provided by six hospitals in Japan to improve its versatility and accuracy.

By significantly increasing the amount of image data through collaboration with the hospitals, the diagnostic tool improved its AI detection of adenocarcinoma of tubular and poorly differentiated types and expanded its AI detection to identify other gastric cancers. It achieved a false negative rate of 0 to 2.5% in seven types of gastric cancer: adenocarcinoma, of tubular, papillary, mucinous and poorly differentiated types, gastrointestinal stromal tumor, MALT lymphoma, and diffuse large B-cell lymphoma. A common AI discrimination threshold was set for all hospitals, demonstrating the improved versatility of the software. As the second research phase continues, Evident aims to further refine the tool to prepare it for commercial use. The goal of this program is to deliver an AI pathology diagnosis software that can assist pathologists by 2023.

Related Links:

Gold Supplier
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
TSI Stimulating Assay
Thyretain TSI Stimulating Reporter BioAssay
Silver Supplier
MDF-U731M-PE Biomedical -30°C Freezer
Cytomegalovirus ELISA Test
Captia Cytomegalovirus (CMV) IgM EIA

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more


view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.